Manufacturer of Controlled Substances; Notice of Registration, 71560-71561 [E5-6592]

Download as PDF 71560 Federal Register / Vol. 70, No. 228 / Tuesday, November 29, 2005 / Notices Dated: November 21, 2005. Joseph T. Rannazzisi, Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E5–6608 Filed 11–28–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated March 29, 2005 and published in the Federal Register on April 6, 2005, (70 FR 17472–17473), Penick Corporation, 158 Mount Olivet Avenue, Newark, New Jersey 07114, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic class of controlled substances listed in Schedule II. Drug Schedule Coca Leaves (9040) ..................... Raw Opium (9600) ....................... Poppy Straw (9650) ..................... Concentrate of Poppy Straw (9670). II II II II The company plans to import the listed controlled substances to manufacturer bulk controlled substances and non-controlled substance flavor extracts. Following the Notice of Application publication on April 6, 2005, (70 FR 17472–17473), Penick Corporation, 158 Mount Olivet Avenue, Newark, New Jersey 07114, relocated its operations to 33 Industrial Park Road, Pennsville, New Jersey 08070 on May 18, 2005. DEA conducted a full investigation and inspection of the company’s security which was found to be in compliance with all required regulations. One comment was received; however, the comment was outside of the required 60-day comment and objection period. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Penick Corporation to import the basic class of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Penick Corporation to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the VerDate Aug<31>2005 20:13 Nov 28, 2005 Jkt 208001 company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substances listed. Dated: November 18, 2005. Joseph T. Rannazzisi, Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E5–6606 Filed 11–28–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated April 14, 2005, and published in the Federal Register on April 25, 2005 (70 FR 10683), Penick Corporation, Inc., 158 Mount Olivet Avenue, Newark, New Jersey, 07114, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic class of controlled substances listed in Schedule II: Drug Schedule Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Ecgonine (9180) ........................... Hydrocodone (9193) ..................... Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... II II II II II II II II II II The company plans to manufacture the listed bulk controlled substances in bulk for distribution to its customers. Following the Notice of Application publication on April 25, 2005, (70 FR 17472–17473), Penick Corporation, 158 Mount Olivet Avenue, Newark, New Jersey 07114, relocated its operations to 33 Industrial Park Road, Pennsville, New Jersey 08070 on May 18, 2005. DEA conducted a full investigation and inspection of the company’s security which was found to be in compliance with all required regulations. One comment was received; however, the comment was not relevant to the company’s current activities as a manufacturer of Schedule II controlled substances. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the PO 00000 Frm 00102 Fmt 4703 Sfmt 4703 registration of Penick Corporation to manufacture the listed basic class of controlled substances is consistent with the public interest at this time. DEA has investigated Penick Corporation to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substances listed. Dated: November 18, 2005. Joseph T. Rannazzisi, Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E5–6607 Filed 11–28–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated June 2, 2005, and published in the Federal Register on June 10, 2005, (70 FR 33923), Research Triangle Institute, Kenneth H. Davis Jr., Herman Building, P.O. Box 12194, East Institute Drive, Research Triangle Park, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: Drug Marihuana (7360) ......................... Cocaine (9041) ............................. Schedule I II The Institute will manufacture small quantities of cocaine and marihuana derivatives for use by their customers primarily in analytical kits, reagents and reference standards. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Research Triangle Institute to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Research Triangle Institute to ensure that the company’s registration is consistent with the public interest. The investigation has included E:\FR\FM\29NON1.SGM 29NON1 Federal Register / Vol. 70, No. 228 / Tuesday, November 29, 2005 / Notices inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: November 21, 2005. Joseph T. Rannazzisi, Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E5–6592 Filed 11–28–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Mine Safety and Health Administration Petitions for Modification The following parties have filed petitions to modify the application of existing safety standards under section 101(c) of the Federal Mine Safety and Health Act of 1977. 1. Emerald Coal Resources, LP [Docket No. M–2005–072–C] Emerald Coal Resources, LP, Three Gateway Center, 401 Liberty Avenue, Suite 1340, Pittsburgh, Pennsylvania 15222 has filed a petition to modify the application of 30 CFR 75.364(b)(1) (Weekly examination) to its Emerald No. 1 Mine (MSHA I.D. No. 36–05466) located in Greene County, Pennsylvania. The petitioner requests a modification of the existing standard to permit the use of air monitoring stations to monitor the longwall tailgate airflow in lieu of traveling the entry in its entirety. The petitioner asserts that due to deteriorating roof conditions, traveling the entry in its entirety would be unsafe. The petitioner asserts that the proposed alternative method would provide at least the same measure of protection as the existing standard. Request for Comments Persons interested in these petitions are encouraged to submit comments via E-mail: zzMSHA–Comments@dol.gov; Fax: (202) 693–9441; or Regular Mail/ Hand Delivery/Courier: Mine Safety and Health Administration, Office of Standards, Regulations, and Variances, 1100 Wilson Boulevard, Room 2350, Arlington, Virginia 22209. All comments must be postmarked or received in that office on or before December 29, 2005. Copies of these VerDate Aug<31>2005 20:13 Nov 28, 2005 Jkt 208001 petitions are available for inspection at that address. Dated at Arlington, Virginia this 22nd day of November 2005. Rebecca J. Smith, Acting Director, Office of Standards, Regulations, and Variances. [FR Doc. E5–6674 Filed 11–28–05; 8:45 am] BILLING CODE 4510–43–P NUCLEAR REGULATORY COMMISSION [Docket Nos. 50–498 and 50–499] STP Nuclear Operating Company, et al.; South Texas Project, Units 1 and 2; Notice of Consideration of Approval of Application Regarding Proposed Corporate Restructuring and Opportunity for a Hearing The U.S. Nuclear Regulatory Commission (the Commission) is considering the issuance of an order under section 50.80 of Title 10 of the Code of Federal Regulations (10 CFR) approving the indirect transfer of Facility Operating License No. NPF–76 and Facility Operating License No. NPF–80 for the South Texas Project, Units 1 and 2 (STP), respectively, to the extent currently held by Texas Genco, LP (Texas Genco). The City Public Service Board of San Antonio, and the City of Austin, Texas, co-own the units with Texas Genco but are not involved in this proposed action. STP Nuclear Operating Company (STPNOC) is authorized to act for the owners, and has exclusive responsibility and control over the physical construction, operation, and maintenance of STP. STP Nuclear Operating Company, acting on behalf of Texas Genco and NRG Energy, Inc. (NRG Energy), has requested that the Commission consent to the indirect transfer of control of Texas Genco’s 44 percent interest in STP. NRG Energy and Texas Genco LLC have entered into a definitive agreement for NRG Energy to acquire all of the outstanding equity of Texas Genco LLC, which indirectly owns 100 percent of Texas Genco. Texas Genco and NRG Energy seek NRC consent to the indirect transfer of control of the licenses to the extent held by Texas Genco that will result from NRG Energy’s acquisition of Texas Genco LLC. In addition to its 44 percent undivided ownership interests in STP, Texas Genco holds a corresponding interest in STPNOC, a not-for-profit Texas corporation, which is the licensed operator of STP. Approval of the indirect transfer of control of the licenses to the extent held by STPNOC PO 00000 Frm 00103 Fmt 4703 Sfmt 4703 71561 is also requested to the extent such approval is necessary. No physical changes to STP or operational changes are being proposed in the application. Pursuant to 10 CFR 50.80, no license, or any right thereunder, shall be transferred, directly or indirectly, through transfer of control of the license, unless the Commission shall give its consent in writing. The Commission will approve an application for the transfer of a license, if the Commission determines that the proposed transferee is qualified to hold the license and that the transfer is otherwise consistent with applicable provisions of law, regulations, and orders issued by the Commission pursuant thereto. Before issuance of the proposed conforming license amendment, the Commission will have made findings required by the Atomic Energy Act of 1954, as amended (the Act), and the Commission’s regulations. The filing of requests for hearing and petitions for leave to intervene, and written comments with regard to the license transfer application, are discussed below. Within 20 days from the date of publication of this notice, any person whose interest may be affected by the Commission’s action on the application may request a hearing and, if not the applicant, may petition for leave to intervene in a hearing proceeding on the Commission’s action. Requests for a hearing and petitions for leave to intervene should be filed in accordance with the Commission’s rules of practice set forth in Subpart C ‘‘Rules of General Applicability: Hearing Requests, Petitions to Intervene, Availability of Documents, Selection of Specific Hearing Procedures, Presiding Officer Powers, and General Hearing Management for NRC Adjudicatory Hearings,’’ of 10 CFR Part 2. In particular, such requests and petitions must comply with the requirements set forth in 10 CFR 2.309. Untimely requests and petitions may be denied, as provided in 10 CFR 2.309(c)(1), unless good cause for failure to file on time is established. In addition, an untimely request or petition should address the factors that the Commission will also consider, in reviewing untimely requests or petitions, set forth in 10 CFR 2.309(c)(1)(i)–(viii). Requests for a hearing and petitions for leave to intervene should be served upon counsel for STPNOC, Mr. John E. Matthews at Morgan, Lewis & Bockius, LLP, 1111 Pennsylvania Avenue, NW., Washington, DC 20004 (tel: 202–739– 5524; fax: 202–739–3001; e-mail: jmatthews@morganlewis.com); counsel E:\FR\FM\29NON1.SGM 29NON1

Agencies

[Federal Register Volume 70, Number 228 (Tuesday, November 29, 2005)]
[Notices]
[Pages 71560-71561]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-6592]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated June 2, 2005, and published in the Federal Register 
on June 10, 2005, (70 FR 33923), Research Triangle Institute, Kenneth 
H. Davis Jr., Herman Building, P.O. Box 12194, East Institute Drive, 
Research Triangle Park, North Carolina 27709, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as a bulk manufacturer of the basic classes of controlled substances 
listed in Schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Marihuana (7360)...........................  I
Cocaine (9041).............................  II
------------------------------------------------------------------------

    The Institute will manufacture small quantities of cocaine and 
marihuana derivatives for use by their customers primarily in 
analytical kits, reagents and reference standards.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Research Triangle Institute to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated Research Triangle Institute to ensure that 
the company's registration is consistent with the public interest. The 
investigation has included

[[Page 71561]]

inspection and testing of the company's physical security systems, 
verification of the company's compliance with state and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above 
named company is granted registration as a bulk manufacturer of the 
basic classes of controlled substances listed.

    Dated: November 21, 2005.
Joseph T. Rannazzisi,
Acting Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration.
[FR Doc. E5-6592 Filed 11-28-05; 8:45 am]
BILLING CODE 4410-09-P